Novartis has announced an agreement with the US government to lower the prices of its medicines in the US and support ...

On December 5, MAPS hosted an educational webinar exploring recent research in Alzheimer’s disease (AD) screening, testing, ...

As part of the three-year agreement, Gilead has agreed to take a series of actions that align with the government’s new drug ...

Merck (known as MSD outside the US) has announced an agreement with the US government to provide key products to patients at ...

Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story ...

Novo Nordisk’s Wegovy (semaglutide) pill has been approved by the US FDA as an oral weight loss medication. In addition to ...

Radical Departures specialises in interactive medical and healthcare communications. Our team combines creativity with extensive medical and scientific experience. We have been designing and ...

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical and biotech clients to ...

PPi specialises in providing guidance and implementation services for healthcare provision. PPi supports the development of market access strategies as well as the ultimate implementation of such ...

We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to solve marketing challenges and drive sustainable change, ...

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to change how we discover rare diseases in the future? Read more to find out.

AbbVie will be gaining rights to IGI Therapeutics’ lead candidate for oncology and autoimmune diseases in an exclusive licensing agreement worth over $1.9bn. ISB 2001 is a trispecific T-cell engager ...